Angiomax™ in Renal Insufficiency Trial
Study of:
Angiomax™ (bivalirudin) drug; sponsored by The Angiomax™ Foundation Program
This trial is designed to examine the clinical benefit associated with the use of Angiomax™ (bivalirudin) in patients undergoing percutaneous coronary intervention (PCI). Patients with renal impairment may have increased risk of bleeding and other complications. Bivalirudin may be a safer drug to use in this group of patients. This study is a randomized trial comparing bivalirudin with two commonly used drugs – heparin, a blood thinner, and eptifibatide, a special IV drug that prevents blood clotting. Approximately 608 patients will be randomized at 3 sites in the United States. Patients will be followed throughout the initial hospitalization and phone calls will be made at 30 days, 6 and 12 months.
- M. Nicholas Burke, MD
- Ivan J. Chavez, MD, FACC
- John R. Lesser, MD, FACC
- Daniel Lips, MD, FACC
- James D. Madison, MD, FACC
- Michael R. Mooney, MD, FACC
- Wesley R. Pedersen, MD, FACC
- Anil K. Poulose, MD, FACC
- Jay H. Traverse, MD, FACC, FAHA
- Yale Wang, MD, FACC, FSCAI
For more information about the interventional cardiology research program at the Minneapolis Heart Institute and Minneapolis Heart Institute Foundation, please contact Carol Stone at 612-863-9124. |